open access

Vol 67, No 3 (2016)
Review paper
Submitted: 2015-11-14
Accepted: 2015-11-15
Published online: 2016-02-01
Get Citation

Diagnosis, treatment, and prognosis in patients with liver metastases from follicular thyroid carcinoma (FTC)

Małgorzata Kałużna, Monika Gołąb, Rafał Czepczyński, Grzegorz Dworacki, Danuta Bręborowicz, Marcin Orłowski, Katarzyna Katulska, Aleksandra Klimowicz, Maria Gryczyńska, Marek Ruchała, Katarzyna Ziemnicka
DOI: 10.5603/EP.a2016.0040
·
Pubmed: 26884308
·
Endokrynol Pol 2016;67(3):332-347.

open access

Vol 67, No 3 (2016)
Reviews — Postgraduate Education
Submitted: 2015-11-14
Accepted: 2015-11-15
Published online: 2016-02-01

Abstract

Follicular thyroid carcinoma (FTC) is the second most common type of thyroid cancer (TC) and accounts for approximately 10% of all TC cases. Liver metastases are a rare presentation in 0.5–1% of follicular thyroid cancers, usually occurring in the setting of widely disseminated FTC disease, and their presence is associated with poor prognosis. Until now, there have been only 30 cases of FTC liver metastases described in the literature.

Herein, we review publications and describe diagnostic tools that may be used in the diagnosis and follow-up of FTC metastases to the liver, including biopsy and imaging techniques like US, CT, MRI, SPECT, PET, and radioiodine scintigraphy. We also present and discuss current methods of treatment, e.g. TSH suppressive therapy with levothyroxine, surgery, radiofrequency ablation (RFA), transarterial embolisation (TAE), liver transarterial chemoembolisation (TACE), chemotherapy with cisplatin and doxorubicin, treatment with Indium- 111-octreotide (or its analogues), and tyrosine kinase inhibitors (sorafenib, sunitinib).

At the end we describe the course, results of diagnostics, and treatment in a patient with large multiple FTC metastases to the liver. (Endokrynol Pol 2016; 67 (3): 332–347)

Abstract

Follicular thyroid carcinoma (FTC) is the second most common type of thyroid cancer (TC) and accounts for approximately 10% of all TC cases. Liver metastases are a rare presentation in 0.5–1% of follicular thyroid cancers, usually occurring in the setting of widely disseminated FTC disease, and their presence is associated with poor prognosis. Until now, there have been only 30 cases of FTC liver metastases described in the literature.

Herein, we review publications and describe diagnostic tools that may be used in the diagnosis and follow-up of FTC metastases to the liver, including biopsy and imaging techniques like US, CT, MRI, SPECT, PET, and radioiodine scintigraphy. We also present and discuss current methods of treatment, e.g. TSH suppressive therapy with levothyroxine, surgery, radiofrequency ablation (RFA), transarterial embolisation (TAE), liver transarterial chemoembolisation (TACE), chemotherapy with cisplatin and doxorubicin, treatment with Indium- 111-octreotide (or its analogues), and tyrosine kinase inhibitors (sorafenib, sunitinib).

At the end we describe the course, results of diagnostics, and treatment in a patient with large multiple FTC metastases to the liver. (Endokrynol Pol 2016; 67 (3): 332–347)

Get Citation

Keywords

differentiated thyroid carcinoma (DTC); follicular thyroid cancer (FTC); liver metastases; positron emission tomography (PET); whole body scintigraphy (WBS)

Supp./Additional Files (3)
Title page in english
Download
21KB
Authors consent 1
View
1MB
Authors consent 2
View
1MB
About this article
Title

Diagnosis, treatment, and prognosis in patients with liver metastases from follicular thyroid carcinoma (FTC)

Journal

Endokrynologia Polska

Issue

Vol 67, No 3 (2016)

Article type

Review paper

Pages

332-347

Published online

2016-02-01

Page views

2523

Article views/downloads

2725

DOI

10.5603/EP.a2016.0040

Pubmed

26884308

Bibliographic record

Endokrynol Pol 2016;67(3):332-347.

Keywords

differentiated thyroid carcinoma (DTC)
follicular thyroid cancer (FTC)
liver metastases
positron emission tomography (PET)
whole body scintigraphy (WBS)

Authors

Małgorzata Kałużna
Monika Gołąb
Rafał Czepczyński
Grzegorz Dworacki
Danuta Bręborowicz
Marcin Orłowski
Katarzyna Katulska
Aleksandra Klimowicz
Maria Gryczyńska
Marek Ruchała
Katarzyna Ziemnicka

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl